ACAT1/SOAT1 as a Therapeutic Target for Alzheimer's Disease
Authors:
- 15 December 2015
- journal article
- review article
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 7 (18) , 2451-2467
Abstract
Alzheimer's disease (AD) is the most common cause of dementia with no cure at present. Cholesterol metabolism is closely associated with AD at several stages. ACAT1 converts free cholesterol to cholesteryl esters, and plays important roles in cellular cholesterol homeostasis. Recent studies show that in a mouse model, blocking ACAT1 provides multiple beneficial effects on AD. Here we review the current evidence that implicates ACAT1 as a therapeutic target for AD. We also discuss the potential usage of various ACAT inhibitors currently available to treat AD.Keywords
Funding Information
- National Institutes of Health (AG37609)
This publication has 132 references indexed in Scilit:
- Upregulated function of mitochondria‐associated ER membranes in Alzheimer diseaseThe EMBO Journal, 2012
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- A lysosome‐to‐nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEBThe EMBO Journal, 2012
- Purification of Recombinant Acyl-Coenzyme A:Cholesterol Acyltransferase 1 (ACAT1) from H293 Cells and Binding Studies between the Enzyme and Substrates Using Difference Intrinsic Fluorescence SpectroscopyBiochemistry, 2010
- Acetylation of Tau Inhibits Its Degradation and Contributes to TauopathyNeuron, 2010
- Fusion Step-Specific Influence of Cholesterol on SNARE-Mediated Membrane FusionBiophysical Journal, 2009
- ApoE Promotes the Proteolytic Degradation of AβNeuron, 2008
- Knockdown of ACAT‐1 reduces amyloidogenic processing of APPFEBS Letters, 2007
- Protein Sensors for Membrane SterolsCell, 2006
- Cholesterol Addition to ER Membranes Alters Conformation of SCAP, the SREBP Escort Protein that Regulates Cholesterol MetabolismMolecular Cell, 2002